Work

Capivasertib treatment associated with hypermetabolism of the spleen

Year: 2025

Type: article

Abstract: Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.

Source: EJNMMI Reports

DOI: 10.1186/s41824-024-00231-7

Authors: Maria Ly, Gary Z. Yu, Amin Haghighat Jahromi

Institution: Washington University in St. Louis

Language: English

Topic: Medical Imaging Techniques and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490